ABT-981 + Placebo for ABT-981
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Erosive Hand Osteoarthritis
Conditions
Erosive Hand Osteoarthritis
Trial Timeline
Mar 1, 2015 → Jul 1, 2016
NCT ID
NCT02384538About ABT-981 + Placebo for ABT-981
ABT-981 + Placebo for ABT-981 is a phase 2 stage product being developed by AbbVie for Erosive Hand Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02384538. Target conditions include Erosive Hand Osteoarthritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02384538 | Phase 2 | Completed |
Competing Products
20 competing products in Erosive Hand Osteoarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH1885L(Revaprazan) + Esomeprazole 20mg + placebo | Yuhan | Phase 2 | 52 |
| E3810 + E3810 + Placebo | Eisai | Phase 3 | 77 |
| RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM | Eisai | Phase 3 | 77 |
| Teprenone capsule and placebo of sucralfate + Sucralfate and placebo of teprenone | Eisai | Approved | 85 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Nexium 20mg + Nexium 10mg | AstraZeneca | Phase 3 | 77 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| AZD0865 | AstraZeneca | Phase 2 | 52 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Esomeprazole + Esomeprazole | AstraZeneca | Approved | 85 |
| AZD0865 | AstraZeneca | Phase 2 | 52 |
| esomeprazole magnesium (oral medication) | AstraZeneca | Approved | 85 |
| Alendronate Effervescent Oral Tablet | Amgen | Phase 2 | 51 |
| Omeprazole/sodium bicarbonate | Bausch Health | Approved | 80 |
| Vonoprazan | Phathom Pharmaceuticals | Phase 1 | 28 |
| Vonoprazan + Lansoprazole | Phathom Pharmaceuticals | Phase 3 | 72 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 2 | 47 |
| Vonoprazan | Phathom Pharmaceuticals | Pre-clinical | 18 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 3 | 72 |